HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam is positioned well fundamentally because its patented three-dimensional ECG platform can synthesize a 12-lead ECG outside the clinic, addressing a large ~$2B market with established reimbursement and a meaningful unmet need in ambulatory cardiac care. The company also has FDA clearance, first commercial partnerships with ClearCardio and Atelier Health, and pilot studies underway for both heart attack detection and an extended-wear patch, which could broaden clinical utility and support future indication expansion. While 1Q26 showed no revenue and a $4.7M net loss, management expects meaningful revenue in 2H26 as flagship account onboarding deepens, with sales scaling and team expansion expected in 2027 and beyond.

HeartBeam is facing a weak fundamental profile because it has effectively paused a broader commercial push for the current arrhythmia product and is now dependent on a much riskier heart attack indication, with no clear visibility on FDA timing or revenue ramp-up. The business remains deeply unprofitable, reporting a 2Q26 net loss of $5.0M and $3.3M in operating cash outflow, while cash stood at only $8.7M at the end of June 2026 after a $11.5M offering in April 2026. Although early studies are progressing, the company still faces substantial clinical, regulatory, dilution, and going-concern risk, and may need to raise additional capital within the next 12 months to fund operations.